Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany

References

• UN. WHO chief declares end to COVID-19 as a global health emergency United Nations. 2023 [cited 2023 Sept 13]. https://news.un.org/en/story/2023/05/1136367.
   Google Scholar
• RKI. COVID-19-Todesfälle in Deutschland. Berlin, Germany: Robert Koch Institute; 2023.
   Google Scholar
• RKI. Decision on the implementation of the COVID-19 vaccination into the general recommendations of the STIKO 2023. Berlin, Germany; Robert Koch Institute; 2023.
   Google Scholar
• Vygen-Bonnet S, Koch J, Bogdan C, et al. Beschluss und wissenschaftliche begründung der ständigen impfkommission (STIKO) für die COVID-19-Impfempfehlung. Epidemiol Bull. 2021;2:3–63.
   Google Scholar
• Koch J, Piechotta V, Berner R, et al. Empfehlung der STIKO zur implementierung der COVID-19-Impfung in die empfehlungen der STIKO 2023 und die dazugehörige wissenschaftliche begründung. Epidemiol Bull. 2023;21:7–48.
   Google Scholar
• Link-Gelles R, Ciesla AA, Roper LE, et al. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to omicron BA.5- and XBB/XBB.1.5-related sublineages among immunocompetent adults - increasing community access to testing program, United States, December 2022–January 2023. MMWR Morb Mortal Wkly Rep. 2023;72(5):119–124. doi: 10.15585/mmwr.mm7205e1.
   PubMed Web of Science ®Google Scholar
• Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION network, September 2022–April 2023. Am J Transplant. 2023;23(7):1062–1076. doi: 10.1016/j.ajt.2023.06.004.
   PubMed Web of Science ®Google Scholar
• WHO. Statement on the antigen composition of COVID-19 vaccines. Geneva: World Health Organization; 2023.
   Google Scholar
• EC. Union Register of medicinal products for human use. European Commission. 2023. https://ec.europa.eu/health/documents/community-register/html/h1507.htm.
   Google Scholar
• Chalkias S, McGhee N, Whatley JL, et al. Safety and immunogenicity of XBB.1.5-containing mRNA vaccines. medRxiv. 2023. doi: 10.1101/2023.08.22.23293434.
   Google Scholar
• PEI. CoV-2 development and authorisation. Langen, Germany: Paul-Ehrlich Institute, Federal Institute for Vaccines and Biomedicines; 2023.
   Google Scholar
• EMA. Spikevax (previously COVID-19 vaccine Moderna) for active immunisation to prevent COVID 19 caused by SARS-CoV-2 in individuals 6 months of age and older. Amsterdam, the Netherlands: European Medicines Agency; 2023.
   Google Scholar
• EMA. Comirnaty: EMA approval of adapted COVID-19 vaccine targeting omicron XBB.1.5. Amsterdam, the Netherlands: European Medicines Agency; 2023.
   Google Scholar
• Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021;385(24):2241–2251. doi: 10.1056/NEJMoa2109522.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi: 10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Hulme WJ, Horne EMF, Parker EPK, et al. Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP. BMJ. 2023;380:e072808. doi: 10.1136/bmj-2022-072808.
   PubMedGoogle Scholar
• Kopel H, Nguyen VH, Boileau C, et al. Comparative effectiveness of bivalent (original/omicron BA.4/BA.5) COVID-19 vaccines in adults. Vaccines. 2023;11(11):1711. doi: 10.3390/vaccines11111711.
   Google Scholar
• Mayr FB, Talisa VB, Shaikh OS, et al. Comparative COVID-19 vaccine effectiveness over time in veterans. Open Forum Infect Dis. 2022;9(7):ofac311.
   PubMed Web of Science ®Google Scholar
• Nguyen VHBC, Bogdanov A. Relative effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines and homologous boosting in preventing COVID-19 in adults in the US. medRxiv. 2023. doi: 10.1101/2023.02.10.23285603.
   Google Scholar
• Ono S, Michihata N, Yamana H, et al. Comparative effectiveness of BNT162b2 and mRNA-1273 booster dose after BNT162b2 primary vaccination against the omicron variants: a retrospective cohort study using large-scale population-based registries in Japan. Clin Infect Dis. 2023;76(1):18–24. doi: 10.1093/cid/ciac763.
   PubMed Web of Science ®Google Scholar
• Wang X, Haeussler K, Spellman A, et al. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework. Front Immunol. 2023;14:1204831. doi: 10.3389/fimmu.2023.1204831.
   PubMedGoogle Scholar
• Bruxvoort KJ, Sy LS, Qian L, et al. Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: interim results from a prospective observational cohort study. Lancet Reg Health Am. 2022;6:100134. doi: 10.1016/j.lana.2021.100134.
   PubMedGoogle Scholar
• Florea A, Sy LS, Luo Y, et al. Durability of mRNA-1273 against COVID-19 in the time of Delta: interim results from an observational cohort study. PLOS One. 2022;17(4):e0267824. doi: 10.1371/journal.pone.0267824.
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Patel MM, Gaglani M, et al. Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults – United States, August-December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(4):118–124. doi: 10.15585/mmwr.mm7104a2.
   PubMed Web of Science ®Google Scholar
• Richards F, Kodjamanova P, Chen X, et al. Economic burden of COVID-19: a systematic review. Clinicoecon Outcomes Res. 2022;14:293–307. doi: 10.2147/CEOR.S338225.
   PubMed Web of Science ®Google Scholar
• Padula WV, Malaviya S, Reid NM, et al. Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis. J Med Econ. 2021;24(1):1060–1069. doi: 10.1080/13696998.2021.1965732.
   PubMed Web of Science ®Google Scholar
• Utami AM, Rendrayani F, Khoiry QA, et al. Economic evaluation of COVID-19 vaccination: a systematic review. J Glob Health. 2023;13:06001. doi: 10.7189/jogh.13.06001.
   PubMed Web of Science ®Google Scholar
• Kohli M, Maschio M, Joshi K, et al. The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States. J Med Econ. 2023;26(1):1532–1545. doi: 10.1080/13696998.2023.2281083.
   PubMedGoogle Scholar
• Shiri T, Evans M, Talarico CA, et al. Vaccinating adolescents and children significantly reduces COVID-19 morbidity and mortality across all ages: a population-based modeling study using the UK as an example. Vaccines. 2021;9(10):1180. doi: 10.3390/vaccines9101180.
   Web of Science ®Google Scholar
• Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLOS Med. 2008;5(3):e74. doi: 10.1371/journal.pmed.0050074.
   PubMed Web of Science ®Google Scholar
• Holstiege J, Akmatov MK, Kohring C, et al. Patients at high risk for a severe clinical course of COVID-19 - small-area data in support of vaccination and other population-based interventions in Germany. BMC Public Health. 2021;21(1):1769. doi: 10.1186/s12889-021-11735-3.
   PubMed Web of Science ®Google Scholar
• Hodcroft E. CoVariants: SARS-CoV-2 mutations and variants of interest. Institute of social and preventive medicine. Switzerland: University of Bern, Switzerland and SIB Swiss Institute of Bioinformatics; 2021.
   Google Scholar
• RKI. Impfquoten bei erwachsenen in deutschland. Robert Koch Institute Epidemiologisches Bulletin. 2022;8:49.
   Google Scholar
• PEI. Seasonal Influenza 2021/2022. Paul Ehrlich Institute, Federal Institute for Vaccines and Biomedicines. 2022. https://www.pei.de/EN/medicinal-products/vaccines-human/influenza-flu/preseasons/influenza-flu-season-2021-2022-content.html.
   Google Scholar
• Tseng HF, Ackerson BK, Sy LS, et al. mRNA-1273 bivalent (original and omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States. Nat Commun. 2023;14(1):5851. doi: 10.1038/s41467-023-41537-7.
   PubMed Web of Science ®Google Scholar
• Pratama NR, Wafa IA, Budi DS, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 omicron variant (B.1.1.529): a systematic review with meta-analysis and meta-regression. Vaccines. 2022;10(12):2180. doi: 10.3390/vaccines10122180.
   Web of Science ®Google Scholar
• Higdon MM, Baidya A, Walter KK, et al. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. Lancet Infect Dis. 2022;22(8):1114–1116. doi: 10.1016/S1473-3099(22)00409-1.
   PubMed Web of Science ®Google Scholar
• IHME. COVID-19 results Hans Rosling Center for population health, University of Washington. Seattle, US: Institute for Health Metrics and Evaluation. 2021. https://covid19.healthdata.org/germany?view=cumulative-deaths&tab=trend
   Google Scholar
• Shang W, Kang L, Cao G, et al. Percentage of asymptomatic infections among SARS-CoV-2 omicron variant-positive individuals: a systematic review and meta-analysis. Vaccines. 2022;10(7):1049. doi: 10.3390/vaccines10071049.
   Web of Science ®Google Scholar
• R Foundation. R: a language and environment for statistical computing. Vienna, Austria: R foundation for Statistical Computing; 2023 [cited 2023 Sept 30]. https://www.R-project.org/
   Google Scholar
• Sim SY, Watts E, Constenla D, et al. Return on investment from immunization against 10 pathogens in 94 low- and middle-income countries, 2011–2030. Health Aff (Millwood). 2020;39(8):1343–1353. doi: 10.1377/hlthaff.2020.00103.
   PubMed Web of Science ®Google Scholar
• Zhou L, Yan W, Li S, et al. Cost-effectiveness of interventions for the prevention and control of COVID-19: Systematic review of 85 modelling studies. J Glob Health. 2022;12:05022. doi: 10.7189/jogh.12.05022.
   PubMed Web of Science ®Google Scholar
• RKI. COVID-19-Hospitalisierungen in Deutschland, Berlin: Zenodo. Robert Koch Institute. 2023. https://github.com/robert-koch-institut/COVID-19-Hospitalisierungen_in_Deutschland#covid-19-hospitalisierungen-in-deutschland.
   Google Scholar
• Wang L, Berger NA, Kaelber DC, et al. COVID infection rates, clinical outcomes, and racial/ethnic and gender disparities before and after omicron emerged in the US. medRxiv. 2022. doi: 10.1101/2022.02.21.22271300.
   Google Scholar
• CGM. Lauer-Taxe® Online 4.0. Spikevax XBB1.5 Injektionsdispersion Einsdos-Fla. 2023. https://portal.cgmlauer.cgm.com/LF/default.aspx?p=12000.
   Google Scholar
• Bilcke J, Coenen S, Beutels P. Influenza-like-illness and clinically diagnosed flu: disease burden, costs and quality of life for patients seeking ambulatory care or no professional care at all. PLOS One. 2014;9(7):e102634. doi: 10.1371/journal.pone.0102634.
   PubMed Web of Science ®Google Scholar
• KBV. Honorarbericht quartal 4 2020. Kassenarztliche Bundesvereinigung. 2020. https://www.kbv.de/media/sp/Honorarbericht_Quartal_4_2020.pdf.
   Google Scholar
• Klaus A. Statistik der bundesagentur für arbeit, grundlagen: Engpassanalyse – methodische weiterentwicklung. Bundesagentur Für Arbeit Statistik/Arbeitsmarktberichterstattung. 2020.
   Google Scholar
• CDC. Isolation and precautions for people with COVID-19. Centers for Disease Control and Prevention. 2023. https://www.cdc.gov/coronavirus/2019-ncov/your-health/isolation.html.
   Google Scholar
• Hollmann M, Garin O, Galante M, et al. Impact of influenza on health-related quality of life among confirmed (H1N1)2009 patients. PLOS One. 2013;8(3):e60477. doi: 10.1371/journal.pone.0060477.
   PubMed Web of Science ®Google Scholar
• Karagiannidis C, Mostert C, Hentschker C, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;8(9):853–862. doi: 10.1016/S2213-2600(20)30316-7.
   PubMed Web of Science ®Google Scholar
• Schilling J, Tolksdorf K, Marquis A, et al. The different periods of COVID-19 in Germany: a descriptive analysis from January 2020 to February 2021. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021;64(9):1093–1106. doi: 10.1007/s00103-021-03394-x.
   PubMed Web of Science ®Google Scholar
• Sandmann FG, Tessier E, Lacy J, et al. Long-term health-related quality of life in non-hospitalized coronavirus disease 2019 (COVID-19) cases with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in England: longitudinal analysis and cross-sectional comparison with controls. Clin Infect Dis. 2022;75(1):e962–e973. doi: 10.1093/cid/ciac151.
   PubMedGoogle Scholar
• PHOSP-COVID. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalization in the UK: a prospective observational study. Lancet Respir Med. 2022;10(8):761–775.
   PubMed Web of Science ®Google Scholar
• Bund-Laender Demografie Portal. Erwerbstaetigenquote nach Alter und Geschlecht, 2000 und 2020. 2023. https://www.demografie-portal.de/DE/Fakten/erwerbstaetigenquote-alter.html.
   Google Scholar
• Destatis. Verdienststrukturerhebung. Niveau, verteilung und zusammensetzung der verdienste und der arbeitszeiten abhangiger beschaftigungsverhaltnisse. Statistiches bundesamt. 2020. www.destatis.de/.
   Google Scholar
• Prosser LA, Harpaz R, Rose AM, et al. A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations. Ann Intern Med. 2019;170(6):380–388. doi: 10.7326/M18-2347.
   PubMed Web of Science ®Google Scholar
• IQWiG. General methods for the assessment of the relation of benefits to costs (version 6.1). institut für qualität und wirtschaftlichkeit im gesundheitswesen. 2022.
   Google Scholar
• RKI. Standardvorgehensweise (SOP) der ständigen impfkommission (STIKO) für die systematische entwicklung von impfempfehlunge. Robert Koch Institute; 2018.
   Google Scholar
• Scholz S, Waize M, Weidemann F, et al. Einfluss von impfungen und kontaktreduktionen auf die dritte welle der SARS-CoV-2-Pandemie und perspektivische rückkehr zu prä-pandemischem kontaktverhalten. Epidemiol Bull. 2021;13:3–22. doi: 10.25646/8256.
   Google Scholar
• Lakdawalla DN, Doshi JA, Garrison LP, et al. Defining elements of value in health care-a health economics approach: an ISPOR special task force report. Value Health. 2018;21(2):131–139. doi: 10.1016/j.jval.2017.12.007.
   PubMed Web of Science ®Google Scholar
• Postma M, Biundo E, Chicoye A, et al. Capturing the value of vaccination within health technology assessment and health economics: country analysis and priority value concepts. Vaccine. 2022;40(30):3999–4007. doi: 10.1016/j.vaccine.2022.04.026.
   PubMed Web of Science ®Google Scholar
• STIKO. Standard operating procedure of the German standing committee on vaccinations (STIKO) for the systematic development of vaccination recommendations. Berlin: Robert Koch Institute. 2018. https://www.rki.de/EN/Content/infections/Vaccination/methodology/SOP.pdf?__blob=publicationFile.
   Google Scholar
• Aidalina M, Khalsom S. COVID-19 vaccination: a systematic review of vaccination strategies based on economic evaluation studies. Med J Malaysia. 2023;78(3):411–420.
   PubMedGoogle Scholar
• Fu Y, Zhao J, Han P, et al. Cost-effectiveness of COVID-19 vaccination: a systematic review. J Evid Based Med. 2023;16(2):152–165. doi: 10.1111/jebm.12525.
   PubMedGoogle Scholar
• Kraft K. COVID-19 Behandlung: kosten pro Patient im fünfstelligen Bereich. PraxisVita: barmer Ersatzkasse. 2020. https://www.praxisvita.de/covid-19-behandlung-kosten-pro-patient-krankenkassen-veroeffentlichen-zahlen-19253.html.
   Google Scholar